Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
المؤلفون المشاركون
Majić, Ana
Miše, Branka Petrić
Matković, Višnja
Belac Lovasić, Ingrid
Katić, Kristina
Canjko, Ivana
Frobe, Ana
Bajić, Žarko
Vrdoljak, Eduard
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-06-20
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Our objective was to assess the safety and efficacy of olaparib in maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma after the partial or complete response to the second or further lines platinum-based chemotherapy in a real-world setting.
We performed a multicenter, real-world observational population-based cohort study on the whole population of Croatian patients initiated to olaparib maintenance therapy between 2016 and 2020.
The primary endpoints were progression-free survival and the discontinuation of treatment because of adverse events.
We enrolled the total population of 69 patients with the median (interquartile range; IQR) age of 53 (48–59), 56 (81%) of them with BRCA1 mutation.
The median (IQR) follow-up was 16 (9–25) months.
Treatment had to be discontinued because of toxicity in 2 (3%) and temporarily interrupted in 14 (20%), while dose was reduced because of toxicity in 18 (26%) of patients.
Toxicity of any grade was observed in 61 (88%) patients and toxicity of grade 3 or 4 in 12 (17%).
Median progression-free survival was 21 (95% CI 16-not calculable) months from the introduction of olaparib, and the median overall survival was not reached.
Our study confirmed efficacy and safety of olaparib as the maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma.
We observed the real-world efficacy and safety comparable to those observed in the randomized controlled trials.
We found the interesting observation of better efficacy of 300 mg tablets, compared to 400 mg capsules, an issue that should be addressed on much larger real-world populations.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Majić, Ana& Miše, Branka Petrić& Matković, Višnja& Belac Lovasić, Ingrid& Katić, Kristina& Canjko, Ivana…[et al.]. 2020. Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology،Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1189032
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Majić, Ana…[et al.]. Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology No. 2020 (2020), pp.1-6.
https://search.emarefa.net/detail/BIM-1189032
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Majić, Ana& Miše, Branka Petrić& Matković, Višnja& Belac Lovasić, Ingrid& Katić, Kristina& Canjko, Ivana…[et al.]. Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology. 2020. Vol. 2020, no. 2020, pp.1-6.
https://search.emarefa.net/detail/BIM-1189032
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1189032
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر